EP3554496A4 - Methods and compositions for treating parkinson's disease - Google Patents

Methods and compositions for treating parkinson's disease Download PDF

Info

Publication number
EP3554496A4
EP3554496A4 EP17880499.3A EP17880499A EP3554496A4 EP 3554496 A4 EP3554496 A4 EP 3554496A4 EP 17880499 A EP17880499 A EP 17880499A EP 3554496 A4 EP3554496 A4 EP 3554496A4
Authority
EP
European Patent Office
Prior art keywords
disease
compositions
methods
treating parkinson
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17880499.3A
Other languages
German (de)
French (fr)
Other versions
EP3554496A1 (en
Inventor
Matthew Carl LAWYER
Carl Henry LAWYER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cove Bio LLC
Original Assignee
Cove Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cove Bio LLC filed Critical Cove Bio LLC
Publication of EP3554496A1 publication Critical patent/EP3554496A1/en
Publication of EP3554496A4 publication Critical patent/EP3554496A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
EP17880499.3A 2016-12-13 2017-12-13 Methods and compositions for treating parkinson's disease Withdrawn EP3554496A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433324P 2016-12-13 2016-12-13
US201762504898P 2017-05-11 2017-05-11
PCT/US2017/066218 WO2018112106A1 (en) 2016-12-13 2017-12-13 Methods and compositions for treating parkinson's disease

Publications (2)

Publication Number Publication Date
EP3554496A1 EP3554496A1 (en) 2019-10-23
EP3554496A4 true EP3554496A4 (en) 2020-05-13

Family

ID=62559231

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17880499.3A Withdrawn EP3554496A4 (en) 2016-12-13 2017-12-13 Methods and compositions for treating parkinson's disease

Country Status (7)

Country Link
EP (1) EP3554496A4 (en)
JP (1) JP2020502269A (en)
CN (1) CN110753543A (en)
AU (1) AU2017376458A1 (en)
CA (1) CA3046501A1 (en)
MX (1) MX2019007041A (en)
WO (1) WO2018112106A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020264076A1 (en) 2019-06-28 2020-12-30 The Procter & Gamble Company Light augmented treatment method
CN113005086B (en) * 2021-02-01 2022-10-28 中国科学院遗传与发育生物学研究所 Application of epothilone D and Apol8 in regulation and control of neural stem cell directional neuron differentiation
CN115813841B (en) * 2023-01-10 2023-09-05 广东迪美新材料科技有限公司 Anti-dandruff itching-relieving composition, preparation method and application thereof, shampoo and preparation method

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021970A2 (en) * 2006-08-09 2008-02-21 Reid William K Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases
US20090062244A1 (en) * 2007-09-04 2009-03-05 Joseph Schwarz Pharmaceutical composition
US20100215775A1 (en) * 2006-10-20 2010-08-26 Symrise Gmbh & Co. Kg Use of c10-c14-alkanediols in the preparation of a composition for the prophylaxis and/or treatment of malassezia-induced dandruff formation
US20100298394A1 (en) * 2007-04-05 2010-11-25 The Johns Hopkins University Antifungal agents as neuroprotectants
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
CA2839350A1 (en) * 2011-07-05 2013-01-10 Contera Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
WO2016079317A1 (en) * 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495538B2 (en) * 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021970A2 (en) * 2006-08-09 2008-02-21 Reid William K Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases
US20100215775A1 (en) * 2006-10-20 2010-08-26 Symrise Gmbh & Co. Kg Use of c10-c14-alkanediols in the preparation of a composition for the prophylaxis and/or treatment of malassezia-induced dandruff formation
US20100298394A1 (en) * 2007-04-05 2010-11-25 The Johns Hopkins University Antifungal agents as neuroprotectants
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
US20090062244A1 (en) * 2007-09-04 2009-03-05 Joseph Schwarz Pharmaceutical composition
CA2839350A1 (en) * 2011-07-05 2013-01-10 Contera Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
WO2016079317A1 (en) * 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRICK P. MICHEL ET AL: "Understanding Dopaminergic Cell Death Pathways in Parkinson Disease", NEURON, vol. 90, no. 4, 18 May 2016 (2016-05-18), US, pages 675 - 691, XP055425720, ISSN: 0896-6273, DOI: 10.1016/j.neuron.2016.03.038 *
VALENTINA S ARSIC ARSENIJEVIC ET AL: "A laboratory-based study on patients with Parkinson?s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production", BMC DERMATOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 1, 14 March 2014 (2014-03-14), pages 5, XP021180748, ISSN: 1471-5945, DOI: 10.1186/1471-5945-14-5 *

Also Published As

Publication number Publication date
AU2017376458A1 (en) 2019-06-27
CN110753543A (en) 2020-02-04
EP3554496A1 (en) 2019-10-23
CA3046501A1 (en) 2018-06-21
JP2020502269A (en) 2020-01-23
WO2018112106A1 (en) 2018-06-21
AU2017376458A2 (en) 2019-08-01
MX2019007041A (en) 2022-09-09

Similar Documents

Publication Publication Date Title
EP3359662A4 (en) Compositions and methods for treating huntington's disease and related disorders
EP3458589A4 (en) Compositions and methods of treating huntington's disease
EP3481402A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3139966A4 (en) Methods and compositions for treating huntington's disease
EP3484504A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3261620A4 (en) Methods and compositions for treating dry eye disease and other eye disorders
EP3402533A4 (en) Methods and compositions for the treatment of neurologic disease
EP3408344A4 (en) Well treatment methods and compositions
EP3377118A4 (en) Methods for treating alzheimer's disease and related disorders
IL263188B (en) Treatment for parkinson's disease
PT3302454T (en) Compositions for use in treating parkinson's disease and related disorders
EP3429598A4 (en) Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
IL277182A (en) Compositions and methods for treating parkinson's disease
EP3347486A4 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3310358A4 (en) Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
EP3554496A4 (en) Methods and compositions for treating parkinson's disease
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3618846A4 (en) Methods and compositions for treating liver disease
EP3398614A4 (en) Agent for preventing and/or treating alzheimer's disease
EP3256151A4 (en) Methods and compositions for treating muscle disease and disorders
EP3538095A4 (en) Methods for treating parkinson's disease
EP3697354A4 (en) Compositions and methods for treating eye disorders
EP3429569A4 (en) Methods for preventing or treating parkinson's disease by the farnesylation of paris
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
EP3423063A4 (en) Compositions and methods for treating addiction or substance use disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190624

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200415

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4174 20060101ALI20200407BHEP

Ipc: A01N 43/40 20060101ALI20200407BHEP

Ipc: A61K 33/14 20060101ALI20200407BHEP

Ipc: A61P 25/16 20060101ALI20200407BHEP

Ipc: A61K 31/4196 20060101ALI20200407BHEP

Ipc: A61K 45/06 20060101ALI20200407BHEP

Ipc: A61K 31/555 20060101ALI20200407BHEP

Ipc: A61K 31/315 20060101AFI20200407BHEP

Ipc: A61K 31/7048 20060101ALI20200407BHEP

Ipc: A61K 31/203 20060101ALI20200407BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201118